Skip to content
Search

Latest Stories

Johnson & Johnson is the world’s most innovative pharmaceutical company

Johnson & Johnson is the world’s most innovative pharmaceutical company

Johnson & Johnson spent £37.1 billion on intangible assets and £11.87 billion on R&D last year

Johnson & Johnson has made it to the list of top 10 most innovative companies in the world released by FOREX.com.


The US-based pharmaceutical company is the fourth most innovative company, scoring 8.23/10 in the innovation index.

Johnson & Johnson is the only pharmaceutical company making it to top 10 list, which makes it the world’s most innovative pharmaceutical company in 2023.

The ranking is based on many factors such as the number of US-registered patents in 2022, the number of R&D expenses over the last 12 consecutive months and their last reported intangible assets.

The health giant spent £37.16 billion on intangible assets (the second highest after Apple), £11.87 billion on R&D last year and registered 1,377 patents last year.

Consumer electronic companies dominated the list, securing the top three spots.

Samsung tops the list with an innovation score of 9.25/10 and the highest number of new patents in 2022 (8,513).

Matthew Weller, Head of Global Market Commentary at FOREX.com, said: “The report's findings underscore Samsung's dominance in the innovation arena, with its leading number of patents reflecting a significant push in consumer electronics. This patent portfolio is not just a measure of quantity but a marker of Samsung's potential to disrupt markets and set new industry standards.”

Despite having spent the most on intangible assets out of all companies, Apple slipped to second position in the list, scoring 9.03/10.

IT giant IBM is in the third place with a score of 8.33/10 and the second highest number of new patents registered in 2022 (4743).

Intel invested 31.6 per cent (£13.6 billion) of their £43 billion revenue - the most out of all companies.

E-commerce giant, Amazon, has invested the most in R&D in the last year (£65 billion).

Experts at FOREX.com have prepared the list by analysing data from Harrity and Seeking Alpha to uncover which companies are the most innovative.

More For You

ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
​The next generation of BD Rowa Smart launched

The latest BD Rowa™ Smart introduces a more intuitive user interface.

Photo credit: BD Rowa

BD Rowa unveils next-generation smart dispensing robot with sustainable design

Leading medical technology company BD Rowa has announced the launch of the next generation of its smart dispensing robot, offering enhanced convenience with a sustainable design.

Currently in its final development phase, the latest BD Rowa™ Smart introduces a more intuitive user interface designed to streamline operations and enhance the user experience.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less